At the ‘Croqui’ symposium held at ‘IMCAS 2024’ on the 3rd, Brazilian dermatologist Dr. Clara Santos is introducing the product’s features.
│Photo courtesy of Samyang Holdings Samyang
Holdings Biopharm Group (CEO Lee Young-jun) presents the features and treatment methods of the lifting thread ‘Croqui’ at the world’s largest international aesthetic plastics society ‘IMCAS (International Master Course on Aging Science) 2024’ held in Paris, France. A symposium was held on.
At this symposium, Won Lee, president of the Association of Minimal Invasive Plastic Surgery (MIPS) of the Korean Society of Plastic Surgery, and Dr. Clara Santos, a Brazilian dermatologist, presented ‘Croqui Master Class: Fat Relocation Procedure Using Double Lifting’. Under the theme of ‘, a procedure using croquis was presented and examples of the procedure were shared.
According to the presentation, during double lifting (lifting technique using two types of threads) using four types of croquis, the fat redistribution effect was found to vary depending on the type and combination of threads and the patient’s skin condition. The presenters introduced various treatment cases and shared the optimal combination of croquis suitable for the treatment area and patient’s condition, and announced that the safety of croquis was proven through patient prognosis. The symposium received a positive response with medical staff and experts from around the world attending and discussing the event.
Croquis is a biodegradable lifting thread that naturally decomposes within the human body after a certain period of time. The main ingredient is polydioxanone (PDO), a biocompatible polymer. It is a technology-intensive product of Samyang Holdings, a global market leader in the field of biodegradable suture yarns, and received certification under the European Medical Devices Directive ‘CE MDD (Medical Devices Directive)’ in 2019. Currently, it is being exported to 29 countries around the world, including Europe, Japan, and Central and South America, and the marketing approval process is also in progress in the United States.
President Lee Won said, “Croqui is a product with excellent treatment effectiveness and safety, and has a very high level of satisfaction among both medical staff and patients.” He added, “Through this symposium, we can share the experience and know-how accumulated through on-site procedures with cosmetic plastic surgery medical staff around the world.” “I think it’s meaningful,” he said.
Panoramic view of Samyang Holdings Biopharm Group’s promotional booth │Photo courtesy of Samyang Holdings
Samyang Holdings opened a promotional booth at this conference and also introduced its self-developed polymer filler ‘Lapulen’. Lapulene’s main ingredient is polycaprolactone (PCL, Polycaprolactone), a biodegradable medical polymer material, and the treatment effect lasts for more than two years. Samyang Holdings’ patented technology is applied, so it is characterized by less foreign body sensation and natural volume. It obtained approval from the Ministry of Food and Drug Safety in 2021, and the excellence of the product was recognized by publishing research results proving its long-term effects in international journals at the Science and Technology Citation Index (SCI) level. It has also entered the global market and is currently launched in Indonesia, and last year, it signed an export-related partnership agreement with a Chinese medical device and aesthetic company.
Youngjun Lee, CEO of Samyang Holdings Biopharm Group, said, “Croqui and Lafuln are cosmetic products developed by concentrating Samyang Group’s long-accumulated polymer research and development capabilities, and there was a lot of interest and inquiries at this symposium.” “We plan to accelerate the expansion of the rapidly growing global cosmetic surgery market based on effectiveness and safety,” he said.